In Asia & Oceania, sales increased 37.1% year on year, to ¥14.9 billion. Sales grew steadily in China. 

Bulk sales and royalty income from Harnal, which are recorded under EMEA sales, declined 11.9% to € 32 million on a euro basis. When converted to yen, sales were up 10.4%, to ¥4.3 billion due to the impact of foreign exchange rates. 

## Funguard/MYCAMINE (Candin-type antifungal agent) 

Sales in Japan decreased 4.5%, to ¥12.3 billion. Funguard’s share in the market of injectable antifungal agents remained high at around 53% during fiscal 2013 (on a value basis). 

In the Americas, sales grew 2.6%, to US$117 million on a U.S. dollar basis. When converted to yen, sales increased 23.7%, to ¥11.7 billion. In terms of patient days per month, MyCAMINE gained a share of around 80% in the U.S. market for injectable candin-type antifungal agents. In the U.S., we obtained approval for an additional pediatric indication in June 2013. 

In EMEA, sales steadily grew by 17.5% to € 65 million, which was a 47.3% increase, to ¥8.8 billion on a yen basis. Distribution of MyCAMINE has expanded to cover 38 European countries. 

In Asia & Oceania, sales grew 44.6%, to ¥3.4 billion, including healthy growth in China. Meanwhile, this product was approved in Australia in May 2013, in Malaysia in August 2013, and in Singapore in December 2013 and sales launched in each of these countries. 

## Protopic (Treatment for atopic dermatitis) 

Sales in Japan increased 1.0%, to ¥3.5 billion. Protopic’s distribution rights in Japan were transferred in April 2014 to Maruho Co., Ltd., which has already been promoting Protopic since April 2011 under an agreement with Astellas. 

In the Americas, sales grew by 22.3%, to US$116 mil- lion on a U.S dollar basis. When converted to yen, sales increased by 47.5%, to ¥11.7 billion. 

In EMEA, sales grew 21.8%, to € 53 million on a euro basis. When converted to yen, sales increased 52.8%, to ¥7.1 billion. 

In Asia & Oceania, sales increased 49.3%, to ¥2.6 billion. 

##  Eligard (Prostate cancer treatment) 

In EMEA, sales decreased 0.5%, to € 139 million on a euro basis. When converted to yen, sales increased 24.7%, to ¥18.7 billion due to the impact of foreign exchange rates. Sales were impacted mainly by price reductions, despite a steady increase in volume due to the contribution of a six-month formulation and other factors. 

In the Asia & Oceania region, this product was launched in Hong Kong in June 2013 and in Thailand in November 2013. 

## XTANDI (prostate cancer treatment) 

In Japan, the Company obtained approval for enzalutamide for the indication of castration-resistant prostate cancer* in March 2014, and it was launched under the brand name XTANDI in May 2014. Through XTANDI, the Company intends to make new treatment options for castration- resistant prostate cancer available in Japan too. Together with Gonax, which is already on the market, the Company expects that XTANDI will help it to make an even greater contribution to prostate cancer treatment. 

In the U.S., XTANDI was launched in September 2012 for the indication of metastatic castration-resistant prostate cancer in patients who have previously received docetaxel (chemotherapy). In the Americas, sales increased steadily to US$450 million compared to US$147 million in fiscal 2012. When converted to yen, sales were ¥45.1 billion, compared to ¥12.2 billion in fiscal 2012. In the market for treatment of castration-resistant prostate cancer in patients who have previous received chemotherapy, XTANDI has steadily expanded its share of this market since launch. It has gained a strong reputation among oncology specialists in terms of both its efficacy and safety. 

In EMEA, XTANDI was launched in the United Kingdom in July 2013, and distribution has expanded to cover 19 European countries (as of July 2014). In fiscal 2013, sales were € 71 million on a euro basis and ¥9.5 billion when converted into yen. The product has made a strong start, with sales expanding in core countries such as the U.K., Germany and France. 

